The Lead Episode 73: A Discussion of Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation

The Lead Episode 73: A Discussion of Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation

In this on-demand activity, William H. Sauer, MD, FHRS, CCDS, Brigham and Women’s Hospital is joined by Rod S. Passman, MD, FHRS, Northwestern University and Graham Peigh, MD, MS, Northwestern Memorial Hospital to discuss the direct oral anticoagulants (DOACs) reduce stroke risk in patients with device-detected atrial fibrillation (DD-AFib) but increase major bleeding risk. The time to benefit (TTB) and time to harm (TTH) are not well quantified.

  • Provider:Heart Rhythm Society
  • Activity Link: https://www.heartrhythm365.org/URL/TheLeadEpisode73
  • Start Date: 2024-08-07 05:00:00
  • End Date: 2024-08-07 05:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 0.25 hours
  • MOC Credit Details: ABIM - 0.25 Point; Credit Type(s): Medical Knowledge (ABIM)
    ABP - 0.25 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
  • Commercial Support: No
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: Clinical Cardiac Electrophysiology, Pediatric Cardiology
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.